[go: up one dir, main page]

PL3761960T3 - Preparat okulistyczny - Google Patents

Preparat okulistyczny

Info

Publication number
PL3761960T3
PL3761960T3 PL19708337.1T PL19708337T PL3761960T3 PL 3761960 T3 PL3761960 T3 PL 3761960T3 PL 19708337 T PL19708337 T PL 19708337T PL 3761960 T3 PL3761960 T3 PL 3761960T3
Authority
PL
Poland
Prior art keywords
ophthalmic formulation
ophthalmic
formulation
Prior art date
Application number
PL19708337.1T
Other languages
English (en)
Inventor
Stefan Sperl
Franz Obermayr
Original Assignee
Kiora Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kiora Pharmaceuticals Gmbh filed Critical Kiora Pharmaceuticals Gmbh
Publication of PL3761960T3 publication Critical patent/PL3761960T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL19708337.1T 2018-03-09 2019-03-08 Preparat okulistyczny PL3761960T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18160981 2018-03-09
PCT/EP2019/055818 WO2019170848A1 (en) 2018-03-09 2019-03-08 Ophthalmic formulation

Publications (1)

Publication Number Publication Date
PL3761960T3 true PL3761960T3 (pl) 2024-04-15

Family

ID=61622364

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19708337.1T PL3761960T3 (pl) 2018-03-09 2019-03-08 Preparat okulistyczny

Country Status (15)

Country Link
US (1) US12472263B2 (pl)
EP (1) EP3761960B1 (pl)
JP (1) JP7081850B2 (pl)
KR (1) KR102496934B1 (pl)
CN (1) CN111163757B (pl)
AU (1) AU2019232153B2 (pl)
BR (1) BR112020017988A2 (pl)
CA (1) CA3092234A1 (pl)
CL (1) CL2020002252A1 (pl)
ES (1) ES2972099T3 (pl)
IL (1) IL276918B2 (pl)
MX (1) MX2020009235A (pl)
PL (1) PL3761960T3 (pl)
WO (1) WO2019170848A1 (pl)
ZA (1) ZA202005233B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6629840B2 (ja) 2014-05-08 2020-01-15 パノプテス・ファーマ・ゲーエムベーハー 眼の疾患および障害を処置するための化合物
IT201900022881A1 (it) * 2019-12-03 2021-06-03 Ntc Srl Budesonide per uso oftalmico in un metodo di trattamento dell’occhio
CN112933075A (zh) * 2019-12-11 2021-06-11 刘力 局部给药的葛根相关药物组合物
US20240199535A1 (en) 2021-04-09 2024-06-20 Immunic Ag Deuterated dhodh inhibitors
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물
CN114577957A (zh) * 2021-12-21 2022-06-03 益诺思生物技术南通有限公司 一种虹膜中伏立康唑药物的检测方法
JP2025500176A (ja) 2021-12-23 2025-01-09 イミュニック アクチェンゲゼルシャフト カルボン酸バイオアイソスタを含むdhodh阻害剤
CA3245254A1 (en) * 2022-03-01 2023-09-07 Kiora Pharmaceuticals Gmbh SALTS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR
TW202506107A (zh) 2023-06-28 2025-02-16 德商埃慕尼克股份公司 雜芳族dhodh抑制劑
CN116687840B (zh) * 2023-08-03 2023-10-20 四川省医学科学院·四川省人民医院 一种用于治疗眼部病状的凝胶制剂及其制备方法
CN118557746A (zh) * 2024-05-30 2024-08-30 四川大学 一种夫西地酸白蛋白复合物及其制备方法与应用
CN120789284A (zh) * 2025-09-18 2025-10-17 通化安睿特生物制药股份有限公司 一种包载环孢菌素a的白蛋白结合型药物及制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61103836A (ja) 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
DD297328A5 (de) 1989-08-18 1992-01-09 �������@���������k���Kk�� 5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
JPH0834320A (ja) * 1994-07-25 1996-02-06 Senshiyaki Service:Kk 車両用の温風乾燥機
CN1124158C (zh) * 1996-04-19 2003-10-15 株式会社·R-技术上野 含白蛋白为有效成分的药物组合物
HUP9701554D0 (en) 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
WO2003006424A1 (en) 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004036182A2 (en) 2002-10-17 2004-04-29 Control Delivery Systems, Inc. Methods for monitoring treatment of disease
BR0317687A (pt) 2002-12-23 2005-11-22 4Sc Ag Compostos aromáticos como agentes antiinflamatórios, imunomoduladores e antiproliferativos
US7365094B2 (en) 2002-12-23 2008-04-29 4Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7071355B2 (en) 2002-12-23 2006-07-04 4 Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056747A1 (en) 2002-12-23 2004-07-08 4Sc Ag Dhodh-inhibitors and method for their identification
AU2005229356B2 (en) * 2004-03-11 2011-06-09 Idorsia Pharmaceuticals Ltd Tetrahydropyridoindole derivatives
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
JP2006089485A (ja) 2004-08-24 2006-04-06 Santen Pharmaceut Co Ltd ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2007038687A2 (en) 2005-09-27 2007-04-05 Aciont, Inc. Ocular administration of immunosuppressive agents
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
JP2009270356A (ja) 2008-05-08 2009-11-19 Yoshinobu Hayashi アスベスト含有被覆層剥ぎ取り物の処理方法
TWI530286B (zh) 2009-05-04 2016-04-21 帕納特斯製藥格斯有限公司 作為抑制病毒化合物之抗發炎劑
US20110021465A1 (en) 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
AU2014390300A1 (en) 2014-04-11 2016-10-20 Panoptes Pharma Gmbh Anti-inflammatory agents as virostatic compounds
JP6629840B2 (ja) 2014-05-08 2020-01-15 パノプテス・ファーマ・ゲーエムベーハー 眼の疾患および障害を処置するための化合物
EP3397625A4 (en) 2015-12-30 2019-12-25 Agios Pharmaceuticals, Inc. TREATMENT OF TUMORS WITH MUTANT ISOCITRATE DEHYDROGENASE
US20240199535A1 (en) 2021-04-09 2024-06-20 Immunic Ag Deuterated dhodh inhibitors
CA3245254A1 (en) 2022-03-01 2023-09-07 Kiora Pharmaceuticals Gmbh SALTS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR
CA3245493A1 (en) 2022-03-09 2023-09-14 Kiora Pharmaceuticals Gmbh POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR

Also Published As

Publication number Publication date
JP2021515777A (ja) 2021-06-24
AU2019232153B2 (en) 2023-07-13
CN111163757B (zh) 2022-04-19
CN111163757A (zh) 2020-05-15
CL2020002252A1 (es) 2021-04-30
BR112020017988A2 (pt) 2020-12-22
IL276918B1 (en) 2024-06-01
EP3761960A1 (en) 2021-01-13
IL276918B2 (en) 2024-10-01
KR20200130280A (ko) 2020-11-18
AU2019232153A1 (en) 2020-09-10
IL276918A (en) 2020-10-29
MX2020009235A (es) 2023-01-16
ES2972099T3 (es) 2024-06-11
ZA202005233B (en) 2022-02-23
KR102496934B1 (ko) 2023-02-06
EP3761960C0 (en) 2023-11-22
US12472263B2 (en) 2025-11-18
EP3761960B1 (en) 2023-11-22
JP7081850B2 (ja) 2022-06-07
WO2019170848A1 (en) 2019-09-12
US20210052737A1 (en) 2021-02-25
NZ767268A (en) 2025-03-28
CA3092234A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
IL276918A (en) Ophthalmic formulation
GB2568579B (en) Ophthalmic drug compositions
CA187445S (en) Goggle
CA187413S (en) Goggle
IL282617A (en) Aerosol formulation
PL3452075T3 (pl) Oftalmiczna kompozycja farmaceutyczna
IL282567A (en) Aerosol formulation
IL282523A (en) Aerosol formulation
GB201801614D0 (en) Formulation
IL282589A (en) Aerosol formulation
GB201816447D0 (en) Formulation
IL282461A (en) Aerosol formulation
IL282697A (en) Aerosol formulation
GB201817863D0 (en) Aerosolisable formulation
CA185177S (en) Goggles
GB201805561D0 (en) Ophthalmic device
IL284688A (en) formulation
GB201913232D0 (en) Aerosolisable formulation
GB201813229D0 (en) Formulation
GB201811926D0 (en) Aerosolisable formulation
GB201807312D0 (en) Formulation
GB201811923D0 (en) Ocular assessment
GB201800635D0 (en) Goggle
HK40044851A (en) Ophthalmic formulation
GB2587402B (en) Formulation